PRELIMINARY RECOMMENDATIONS FOR REGISTRATION OF ADVANCED THERAPY MEDICINAL PRODUCTS: THE CASE OF CELL THERAPY MEDICINAL PRODUCTS IN THAILAND
DOI:
https://doi.org/10.69598/tbps.17.1.71-92Keywords:
advanced therapy medical products, cell therapy, drug registrationAbstract
Medical treatment has evolved rapidly and is being increasingly tailored for specific diseases of particular patients, leading to an emergence of Advanced Therapy Medicinal Products (ATMPs). These ATMPs entail cell therapy medicinal products which are derived from both patients themselves and other individuals. Because the products are made specific to each patient, the amount of production is smaller than the production of other medical products. Henceforth, there is a need for regulatory bodies to come up with new regulation for drug registration to be applied to cell therapy medicinal products in Thailand. The objective of this study is to formulate such preliminary recommendations for drug registration. This is qualitative research conducted through semi-structured questionnaire with 19 key informants, purposively selected, which entail members of regulatory bodies dealing with medical products in the government and entrepreneurs, which encompass manufacturers and importers who are licensed with Drug Act B.E. 2510. It is found that cell therapy medicinal products are different from biologic drugs; therefore, regulations should be different in certain dimensions. For example, risk management should be an element of conditional approval of drug registration, since autologous medical products are being produced in limited amount there should be other pathway of examination that do not require the drug samples themselves before authorization for marketing, issuance of Certificate of Lot Release, and retainment of drug samples, and risk-based: SMP level 1 follow-up should be implemented, whereby patients are followed up actively in the first two years and regularly thereafter. Other than that Thai FDA freely able to tailor made following up procedure of patients of cell therapy medicinal products in order to better protect consumers of the products. At the moment, cell therapy medicinal products have not been registered in Thailand. Thus, Thai FDA is the main institution in oversight the health products with supports from the Department of Medical Sciences and they should be equipped with knowledge, laboratory capabilities, and manpower for cell therapy medicinal products to be registered in Thailand.
References
European Medicines Agency. Reflection paper on classification of advanced therapy medicinal products [Internet]. 2015 [cited 2019 May 9]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf
Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11-22.
Li MD, Atkins H, Bubela T. The global landscape of stem cell clinical trials. Regen Med. 2014;9(1):27-39.
Hanna E, Rémuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: current and future perspectives. J Mark Access Health Policy. 2016;4(1):31036.
Lindvall O, Björklund A. Cell replacement therapy: helping the brain to repair itself. NeuroRx. 2004;1(4):379-381.
Food and Drug Administration.Announcement of regulation on advanced therapy medicinal Products [Internet]. 2018 [cited 2019 May 29]. Available from: https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Law04-Notification-ThFDA/FDA-20180510.pdf
United state Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. proposed approach to regulation of cellular and tissue-based products. [online]. 1997 [cited 2019 May 29]. Available from: https://www.fda.gov/media/70704/download
Bonini C, Mondino A. Adoptive T-cell therapy for cancer: The era of engineered T cells. Eur J Immunol. 2015;45(9):2457-69.
June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359(6382):1361-1365.
Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol. 2014;99(4):361-371.
Gionet-Gonzales MA, Leach JK. Engineering principles for guiding spheroid function in the regeneration of bone, cartilage, and skin. Biomed Mater. 2018;13(3):034109.
United State Food and Drug Administration. maci-autologous-cultured-chondrocytes-porcine-collagen-membrane [Internet]. 2019 [cited 2019 Jun 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane
Miyamura K. Insurance approval of mesenchymal stem cell for acute GVHD in Japan: need of follow up for some remaining concerns. Int J Hematol. 2016;103(2):155-164.
European Medicines Agency. Alofosel [Internet]. 2018 [cited 2019 May 9]. Available from: https://www. ema.europa.eu/en/medicines/human/EPAR/alofisel.
United State Food and Drug Administration. Approved cellular and gene therapy products [Internet]. 2021 [cited 2019 Dec 22]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products
The Alliance for Regenerative Medicine Organization. Regenerative medicine in 2021: a year of firsts and records [Internet]. 2019 [cited 2019 Jun 10]. Available from: http://alliancerm.org/wp-content/uploads/2021/08/ARM-H1-2021-Report.pdf
Prasongtanakij S, Anurathapan U, Vanichapol T, et al Production and characterization of haploidentical CD19 CAR T cells: validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL [published online ahead of print, 2020 Sep 24]. Asia Pac J Clin Oncol. 2020;10.1111/ajco.13474.
Prabhasawat P, Ekpo P, Uiprasertkul M, Chotikavanich S, Tesavibul N. Efficacy of cultivated corneal epithelial stem cells for ocular surface reconstruction. Clin Ophthalmol. 2012;6:1483-1492.
Pearce, KF, Hildebrandt, M, Greinix, H, Scheding, S, Koehl, U, Worel, N et al. (2014). Regulation of advanced therapy medicinal products in Europe and the role of academia. Cytotherapy 16: 289– 297.
De Wilde S, Guchelaar HJ, Zandvliet ML, Meij P. Clinical development of gene- and cell-based therapies: overview of the European landscape. Mol Ther Methods Clin Dev. 2016;3:16073.
FDA Approves Personalized Cellular Therapy for Advanced Leukemia Developed by University of Pennsylvania and Children’s Hospital of Philadelphia [Internet] .2017 [cited 2021 May 9]. Available from: https://www.pennmedicine.org/news/news-releases/ 2017/august/fda-approves-personalized-cellular-therapy-for-advanced-leukemia
Thai Food and drug Administration.The declaration to regulate on advanced therapy medical products [Internet] .2018 [cited 2019 May 9]. Available from: https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Law04-Notification-ThFDA/FDA-20180307.pdf
United state Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research. Expedited Programs for Regenerative Medicine Therapies for Serious Conditions. U.S. Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research [Internet]. 2014 [cited 2019 Jan 24] Available from: https://www.fda.gov/media/120267/download
Azuma K. Regulatory landscape of regenerative medicine in Japan. Cur Stem Cell Rep. 2015;1(2):118-28.
European Medicines Agency. Questions and answers on the exemption from batch controls carried out on ATMPs imported into the European Union from a third country [Internet]. 2019 [cited 2021 Nov 22]. Available from: https://www.ema.europa.eu/en/documents/other/questions-answers-exemption-batch-controls-carried-out-atmps-imported-european-union-third-country_en.pdf
Pharmaceutical inspection convention pharmaceutical inspection co-operation scheme. Guide to good manufacturing practice for medicinal products annexes [Internet]. 2021 [cited 2021 Nov 22]. Available from: https://picscheme.org/docview/4102
Nagai S. Flexible and expedited regulatory review processes for innovative medicines and regenerative medical products in the US, the EU, and Japan. Int J Mol Sci. 2019;20(15):3801.
European Medicines Agency. Guidelines on good clinical practice specific to Advanced Therapy Medicinal Products [Internet]. 2019 [cited 2019May 29]. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-10/atmp_guidelines_en.pdf.
European Medicines Agency.Draft guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials [online]. 2019 [cited 2019 May 29]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy_en.pdf.
Thai Food and Drug Administration. The declaration of risk base approach safety monitoring program [Internet]. 2018 [cited 2019 May 29]. Available from: https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Law04-Notification-ThFDA/risk-based-approach-safety-monitoring-program.pdf.
European Medicines Agency. guideline on safety and efficacy follow-up - risk management of advanced therapy medicinal products [Internet]. 2008 [cited 2019 May 15]. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/Regulatory_and_procedural_guideline/2009/10/WC500006326.pdf
Sipp D, Okano H. Japan strengthens regenerative medicine oversight. Cell stem cell. 2018;22(2):153-6.
Tobita M, Konomi K, Torashima Y, Kimura K, Taoka M, Kaminota M. Japan's challenges of translational regenerative medicine: act on the safety of regenerative medicine. Regen Ther. 2016;4:78-81.
Therapeutic Goods Administration. Autologous human cells and tissues products regulation Australian Regulatory Guidelines for Biologicals (ARGB) [Internet]. 2019 [cited 2020 May 9]. Available from: https://www.tga.gov.au/autologous-human-cells-and-tissues-products-regulation.
Warner E. Goodbye Glybera! the World’s first gene therapy will be withdrawn [Internet]. 2017 [cited 2021 Dec 22]. Available from: https://www.labiotech.eu/trends-news/uniqure-glybera-marketing-withdrawn/
McConaghie A. Glybera, the most expensive drug in the world, to be withdrawn after commercial flop [Internet]. 2017 [cited 2021 Dec 22]. Available from: https://pharmaphorum.com/news/glybera-expensive-drug-world-withdrawn-commercial-flop/
Downloads
Published
How to Cite
Issue
Section
License
All articles published and information contained in this journal such as text, graphics, logos and images is copyrighted by and proprietary to the Thai Bulletin of Pharmaceutical Sciences, and may not be reproduced in whole or in part by persons, organizations, or corporations other than the Thai Bulletin of Pharmaceutical Sciences and the authors without prior written permission.
